Vectus Biosystems logo

VBS - Vectus Biosystems News Story

A$1.3 0.0  0.0%

Last Trade - 23/07/21

Sector
Healthcare
Size
Micro Cap
Market Cap £22.1m
Enterprise Value £21.8m
Revenue £54.3k
Position in Universe 1210th / 1940

BUZZ-Vectus Biosystems climbs on nod for lead drug's Phase I trial in Australia

Thu 17th June, 2021 2:21am
** Vectus Biosystems Ltd  VBS.AX  rises as much as 15.8% to
A$1.170, on track for its best session since Dec. 23, 2020
    ** The biotech company says it received approval for the
Phase I human trial of its drug, dubbed VB0004, in healthy
volunteers in Australia to study its safety and tolerability
 urn:newsml:reuters.com:*:nASX24Bfhn
    ** VB0004 is co's lead compound, which aims to treat the
hardening of functional tissue and high blood pressure
    ** Stock hits highest since April 19; More than 51,000
shares change hands vs 30-day average volume of about 27,000
    ** Stock down 15.8% this year, as of last close

 (Reporting by Rashmi Ashok in Bengaluru)
 ((Rashmi.Ashok@thomsonreuters.com; +918061822604;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.